• Oncoinvent expects its cash runway to extend into the second half of 2027, beyond its April interim efficacy readout.
• A September 2026 private placement and retail offering raised NOK 148.5 million in gross proceeds, funding Phase 3 readiness.
• Phase 2 recruitment is expected to finish in the first half of 2027; 71 patients were enrolled by September 30, 2026.
• The April 2027 efficacy readout is expected to include twice as many patients with at least nine months of follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.